Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CTMX logo CTMX
Upturn stock ratingUpturn stock rating
CTMX logo

CytomX Therapeutics Inc (CTMX)

Upturn stock ratingUpturn stock rating
$2.49
Last Close (24-hour delay)
Profit since last BUY211.25%
upturn advisory
Regular Buy
BUY since 46 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/09/2025: CTMX (3-star) is a REGULAR-BUY. BUY since 46 days. Profits (211.25%). Updated daily EoD!

Upturn Star Rating

rating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

6 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $5.5

1 Year Target Price $5.5

Analysts Price Target For last 52 week
$5.5 Target price
52w Low $0.4
Current$2.49
52w High $3.1

Analysis of Past Performance

Type Stock
Historic Profit 63.61%
Avg. Invested days 29
Today’s Advisory Regular Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/09/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 378.11M USD
Price to earnings Ratio 5
1Y Target Price 5.5
Price to earnings Ratio 5
1Y Target Price 5.5
Volume (30-day avg) 6
Beta 2.12
52 Weeks Range 0.40 - 3.10
Updated Date 07/9/2025
52 Weeks Range 0.40 - 3.10
Updated Date 07/9/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.48

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 28.2%
Operating Margin (TTM) 44.43%

Management Effectiveness

Return on Assets (TTM) 15.87%
Return on Equity (TTM) -5475.03%

Valuation

Trailing PE 5
Forward PE 7.27
Enterprise Value 306369485
Price to Sales(TTM) 2.56
Enterprise Value 306369485
Price to Sales(TTM) 2.56
Enterprise Value to Revenue 2.08
Enterprise Value to EBITDA 8.14
Shares Outstanding 157544000
Shares Floating 60863433
Shares Outstanding 157544000
Shares Floating 60863433
Percent Insiders 0.83
Percent Institutions 51.02

ai summary icon Upturn AI SWOT

CytomX Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

CytomX Therapeutics, Inc. was founded in 2008. It focuses on developing probody therapeutics, designed to target cancer cells while minimizing impact on healthy tissue. The company has evolved through partnerships and clinical trials to advance its pipeline.

business area logo Core Business Areas

  • Probody Therapeutics: Development of masked antibodies (Probody therapeutics) that are activated in the tumor microenvironment, reducing off-target toxicity. This includes research, preclinical development, and clinical trials.
  • Immuno-Oncology: Focusing on immuno-oncology targets to stimulate the patient's immune system against cancer cells. This often involves combination therapies.
  • Antibody-Drug Conjugates (ADCs): Developing ADCs using its probody technology, delivering cytotoxic payloads directly to cancer cells.

leadership logo Leadership and Structure

Sean McCarthy is the CEO. The company structure includes research and development, clinical operations, and corporate functions like finance and legal.

Top Products and Market Share

overview logo Key Offerings

  • CX-2029 (Probody ADC targeting CD71): CX-2029 is an ADC targeting CD71, a receptor overexpressed in many cancers. It is in clinical development. There is no current market share as it's pre-commercial. Competitors include companies developing similar ADCs, such as Daiichi Sankyo, Seagen (now part of Pfizer), and Immunomedics (now part of Gilead).
  • CX-904 (Probody T-cell Engaging Bispecific): CX-904 is a conditionally active T-cell engaging bispecific antibody targeting EGFR on tumor cells and CD3 on T cells. It is in clinical development. There is no current market share as it's pre-commercial. Competitors include companies developing similar bispecific antibodies, such as Amgen and Roche.

Market Dynamics

industry overview logo Industry Overview

The oncology market is large and competitive, driven by unmet needs and technological advancements. Immuno-oncology and targeted therapies like ADCs are major growth areas. There is intense competition and rapid innovation.

Positioning

CytomX is positioned as an innovator in the field of conditionally activated antibodies, aiming to improve the safety and efficacy of cancer therapies. Its competitive advantage lies in its Probody technology.

Total Addressable Market (TAM)

The total addressable market for cancer therapies is estimated to be over $200 billion. CytomX is targeting specific niches within this market with its Probody platform, aiming to capture a share of the ADC and immuno-oncology segments.

Upturn SWOT Analysis

Strengths

  • Proprietary Probody technology
  • Potential for reduced off-target toxicity
  • Strong partnerships with pharmaceutical companies
  • Focus on innovative cancer therapies

Weaknesses

  • Clinical development risk
  • Dependence on partnerships for funding
  • Limited number of commercialized products
  • Competition from established players

Opportunities

  • Expansion of Probody technology to new targets
  • Potential for combination therapies
  • Growth in the ADC market
  • Increased demand for safer and more effective cancer treatments

Threats

  • Clinical trial failures
  • Competition from other drug developers
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • PFE
  • BMY
  • MRK

Competitive Landscape

CytomX's probody technology provides a potential advantage in terms of safety and efficacy. However, it faces competition from larger companies with more resources and established products.

Major Acquisitions

No acquisitions to report

  • Year: 0
  • Acquisition Price (USD millions): 0
  • Strategic Rationale: None

Growth Trajectory and Initiatives

Historical Growth: Growth has been driven by the advancement of its pipeline and the signing of collaboration agreements. However, the company has not yet achieved profitability.

Future Projections: Future growth depends on the success of its clinical trials and its ability to secure additional partnerships. Analyst estimates vary widely.

Recent Initiatives: Recent initiatives include advancing clinical trials of its lead programs (CX-2029, CX-904) and expanding its collaboration with BMS.

Summary

CytomX Therapeutics is an innovative company developing Probody therapeutics. Their Probody platform is designed to improve the safety and efficacy of cancer treatments, but has had limited success in the market and only a small market share. Clinical trial successes and securing partnerships are key to future growth. The company needs to mitigate risks associated with clinical development and competition from established players.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • CytomX Therapeutics Investor Relations
  • SEC Filings
  • Analyst Reports
  • Company Website

Disclaimers:

This analysis is based on available information and is not financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share data are estimates.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About CytomX Therapeutics Inc

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2015-10-08
Chairman & CEO Dr. Sean A. McCarthy DPHIL
Sector Healthcare
Industry Biotechnology
Full time employees 119
Full time employees 119

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.